FDA
-
-
-
-
-
-
-
Leerink on Compass Therapeutics (CMPX): 'there are multiple sources of long-term upside'
-
-
-
-
-
-
-
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
-
-
-
-
-
-
-
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
-
-
-
-
-
-
-
Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position
-
-
-
-
-
-
-
Compass Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-
323,150 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

